FibroGen, Inc (NASDAQ:FGEN)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a note issued to investors on Thursday. They currently have a $80.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 52.67% from the stock’s previous close.

FGEN has been the subject of several other reports. Citigroup Inc. boosted their target price on FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a report on Tuesday, August 8th. BidaskClub downgraded FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. William Blair reissued an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Jefferies Group LLC assumed coverage on FibroGen in a report on Monday, July 10th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. FibroGen currently has an average rating of “Buy” and an average price target of $60.17.

FibroGen (NASDAQ:FGEN) opened at 52.40 on Thursday. The firm’s market capitalization is $3.73 billion. The stock has a 50 day moving average price of $43.31 and a 200-day moving average price of $32.07. FibroGen has a one year low of $15.60 and a one year high of $52.70.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The firm had revenue of $29.00 million during the quarter, compared to analysts’ expectations of $34.80 million. On average, analysts predict that FibroGen will post ($1.80) earnings per share for the current fiscal year.

WARNING: “FibroGen, Inc (FGEN) Rating Reiterated by Stifel Nicolaus” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/fibrogen-inc-fgen-rating-reiterated-by-stifel-nicolaus.html.

In other FibroGen news, VP Pat Cotroneo sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $30.00, for a total transaction of $165,000.00. Following the transaction, the vice president now owns 168,866 shares in the company, valued at approximately $5,065,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $31.52, for a total value of $1,217,806.72. Following the transaction, the chief executive officer now owns 3,330,780 shares in the company, valued at approximately $104,986,185.60. The disclosure for this sale can be found here. Insiders sold a total of 509,328 shares of company stock worth $21,719,918 in the last 90 days. 14.90% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in FibroGen by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after purchasing an additional 761,421 shares during the period. BlackRock Inc. increased its position in FibroGen by 12.3% during the 2nd quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock worth $161,545,000 after purchasing an additional 546,587 shares during the period. FMR LLC increased its position in FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after purchasing an additional 1,641,423 shares during the period. State Street Corp increased its position in FibroGen by 16.4% during the 2nd quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock worth $56,962,000 after purchasing an additional 248,922 shares during the period. Finally, Hillhouse Capital Management Ltd. increased its position in FibroGen by 75.0% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $56,525,000 after purchasing an additional 750,000 shares during the period. Institutional investors own 47.49% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.